Tumour but not stromal expression ofβ3 integrin is essential, and is required early, for spontaneous dissemination of bone-metastatic breast cancer

Bone-derived soluble factors and laminin-511 cooperate to promote migration, invasion and survival of bone-metastatic breast tumor cells

(2014) Delphine Denoyer et al.   GROWTH FACTORS

Vascular Endothelial Growth Factor-d Modulates Caliber and Function of Initial Lymphatics in the Dermis

(2013) Sophie Paquet-Fifield et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer

(2012) Christian Manegold et al.   INVESTIGATIONAL NEW DRUGS

A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma

(2012) Kevin B. Kim et al.   MELANOMA RESEARCH

Integrin Targeted Therapeutics

(2012) Melissa Millard et al.   Theranostics

Integrin-dependent response to laminin-511 regulates breast tumor cell invasion and metastasis

(2011) Nicole Kusuma et al.   INTERNATIONAL JOURNAL OF CANCER

Clinical and pharmacologic evaluation of two dose levels of intetumumab (CNTO 95) in patients with melanoma or angiosarcoma

(2011) Steven J. O’Day et al.   INVESTIGATIONAL NEW DRUGS

Identification of vitronectin as a novel serum marker for early breast cancer detection using a new proteomic approach

(2011) Masami Kadowaki et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Integrin Inhibitors as a Therapeutic Agent for Ovarian Cancer

(2011) Kenjiro Sawada et al.   Journal of Oncology

Integrins and bone metastasis: Integrating tumor cell and stromal cell interactions

(2010) Jochen G. Schneider et al.   BONE

A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin αvβ3, ± dacarbazine in patients with stage IV metastatic melanoma

(2010) Peter Hersey et al.   CANCER

Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium

(2010) Ajjai Alva et al.   INVESTIGATIONAL NEW DRUGS

Improved Detection of Regional Melanoma Metastasis Using 18F-6-Fluoro-N-[2-(Diethylamino)Ethyl] Pyridine-3-Carboxamide, a Melanin-Specific PET Probe, by Perilesional Administration

(2010) D. Denoyer et al.   JOURNAL OF NUCLEAR MEDICINE

The platelet contribution to cancer progression

(2010) N. M. BAMBACE et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

β 3 -Integrin Expression on Tumor Cells Inhibits Tumor Progression, Reduces Metastasis, and Is Associated with a Favorable Prognosis in Patients with Ovarian Cancer

(2009) Swayamjot Kaur et al.   AMERICAN JOURNAL OF PATHOLOGY

Inhibition of metastasis in a murine 4T1 breast cancer model by liposomes preventing tumor cell-platelet interactions

(2009) Jane Wenzel et al.   CLINICAL & EXPERIMENTAL METASTASIS

Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme

(2008) David A. Reardon et al.   JOURNAL OF CLINICAL ONCOLOGY